Sonirid Duo set of tablets and capsules 0,4 + 5mg, No. 60
Expiration Date: 05/2027
Russian Pharmacy name:
Сонирид Дуо набор таблеток и капсул 0,4+5мг, №60
Treatment and control of symptoms of benign prostatic hyperplasia (BPH).
Inside. The drug is intended for daily use. The daily dose of Sonirid Duo includes 1 capsule. tamsulosin 0.4 mg and 1 tab. finasteride 5 mg.
Tamsulosin 0.4 mg must be taken at the same time of day, after meals. The capsules should be swallowed whole, do not crush or chew. this can interfere with the sustained release of the active ingredient.
For a full therapeutic effect, long-term use of the drug Sonirid Duo is necessary. If adverse reactions occur, the patient can be transferred to monotherapy with finasteride; however, it is recommended to return to the combination regimen if BPH symptoms increase.
| Pills and capsules set | |
| Film-coated tablets | 1 tab. |
| active substance: | |
| finasteride | 5 mg |
| Excipients | |
| core: magnesium stearate - 0.75 mg; talc - 4.5 mg; sodium carboxymethyl starch (type A) - 7.5 mg; pregelatinized starch - 15 mg; MCC - 15 mg; lactose monohydrate - 102.25 mg | |
| film shell: titanium dioxide (CI77891, EEC171) - 0.1881 mg; lactose monohydrate - 0.3809 mg; macrogol 6000 - 0.6214 mg; hyprolosis - 1.9048 mg; hypromellose - 1.9048 mg | |
| Modified release capsules | 1 caps. |
| active substance: | |
| tamsulosin hydrochloride | 0,4 mg |
| excipients: calcium stearate - 0.8 mg; triethyl citrate - 1.1 mg; talc - 2.5 mg; methacrylic acid and ethyl acrylate copolymer (1: 1) (also containing polysorbate 80 - 1 mg, sodium lauryl sulfate - 0.3 mg) - 43.8 mg; MCC - 281.4 mg | |
| hard gelatin capsule | |
| cap: iron dye yellow oxide (CI77492, E172) - 0.2%; titanium dioxide (CI77891, E171) - 0.3333%; iron dye black oxide (CI77499, E172) - 0.53%; iron dye red oxide (CI77491, E172) - 0.93%; gelatin - up to 100% | |
| body: iron dye red oxide (CI77491, E172) - 0.01%; iron dye black oxide (CI77499, E172) - 0.01%; iron dye yellow oxide (CI77492, E172) - 0.1714%; titanium dioxide (CI77891, E171) - 3%; gelatin - up to 100% |
hypersensitivity to active or auxiliary substances;
a history of postural hypotension;
severe liver failure;
impaired renal function (plasma creatinine concentration> 2 mg / dl);
galactose intolerance, lactase deficiency or glucose-galactose malabsorption;
female;
childhood.
With care: there is a risk of developing obstructive uropathy; liver disease; planning of surgical treatment of cataracts.